Anabolic steroid side effects in women can include voice deepening, facial hair growth, scalp hair loss, acne, genital changes and disrupted periods. Heart, liver and mental health effects also matter, even when they do not change how someone looks.
Some effects can improve after exposure ends, while others can persist. Research cannot provide a dependable recovery timetable or a cycle that guarantees a return to baseline.
The useful question is which outcome a study actually followed: symptoms, a laboratory measurement, fertility, everyday function or recovery after treatment. Those answers are often different.
Image context: The featured photograph illustrates strength; muscular appearance alone does not establish anabolic steroid use.
Anabolic steroid side effects in women at a glance
Anabolic-androgenic steroids, or AAS, include testosterone and related drugs used nonmedically to increase muscle or performance. They differ from corticosteroid medicines used for conditions such as inflammation.
Androgen effects can involve the voice, skin, hair follicles and reproductive system. A product described as mild or mostly anabolic does not come with a promise that these tissues will be unaffected.
| Area | Possible effects | What recovery claims need to acknowledge |
|---|---|---|
| Voice | Lower pitch, hoarseness, instability or vocal fatigue | Changes can persist; improvement in one measure does not establish full restoration. |
| Skin and hair | Acne, facial or body hair growth, scalp hair loss | Skin improvement, scarring and hair regrowth are separate outcomes. |
| Reproductive function | Infrequent or absent periods and disrupted ovulation | A period returning does not measure every aspect of fertility or overall health. |
| Genital and breast tissue | Clitoral enlargement or reduced breast size | Anatomical change may persist; an individual result cannot be predicted from a cycle description. |
| Heart and circulation | Adverse cholesterol changes, blood pressure effects and serious cardiovascular problems | A better risk marker is not proof that all cardiovascular consequences have resolved. |
| Liver and kidneys | Injury, including liver problems associated with some oral agents | Assessment depends on the exposure and clinical findings, not appearance alone. |
| Mental health | Mood changes, anxiety, depression or dependence | Problems can occur during use and withdrawal; support may be needed. |
The NHS overview and Mayo Clinic risk guide describe these effects. Neither supplies a reliable percentage of women who will recover each function after nonmedical AAS use.
What human studies actually measured
Human evidence includes controlled hormone studies, people seeking treatment and interviews with current or former users. These designs answer different questions, and none represents every woman using an unknown product or combination.
| Human evidence | Who was studied | What was measured | What it cannot establish |
|---|---|---|---|
| 2015 randomized voice analysis | Women with low testosterone after hysterectomy, receiving estrogen and assigned testosterone or placebo | Acoustic pitch and a questionnaire about voice impact | A safe bodybuilding cycle or the probability of recovery after stopping |
| Voice clinic case series | Nine women presenting with voice complaints after androgen supplementation | Clinical voice findings and follow-up in five patients | How often voice problems occur among all users or a treatment success rate |
| Twenty-year voice case | One former bodybuilder with voice change after a short exposure | Voice function, examinations and a course involving several procedures | A universal timeline, a fixed lifetime voice state or an explanation for every later symptom |
| Interviews with 16 women | Current or former AAS users | Experiences of physical changes, sexuality and social consequences | Population rates or objectively confirmed fertility and recovery probabilities |
In the study of a 24-week testosterone intervention, 71 women were randomized, but the voice report analyzed 46 with available outcome data. Its table lists 36 with acoustic measurements and 41 with questionnaire data, so 71 is not the denominator for every voice finding.
Higher treatment groups had measurable pitch reductions, while self-reported voice handicap did not change significantly compared with placebo. Not noticing a problem and having no measurable change were different results.
The analysis was exploratory, had small groups and did not adjust for multiple comparisons. Although the trial design included a recovery period, this voice report does not provide a post-cessation recovery result.
The interview study adds another kind of information: participants described using the loss and return of periods to judge when to start another cycle. That reports a decision people made; it does not validate menstruation as a medical clearance test.
Voice changes can persist without following one path
Androgens can affect the larynx and lower pitch. A 2025 scoping review identified 14 studies and reported that results varied with dose, duration and delivery route, with inadequate consensus on avoiding potentially irreversible voice effects.
That review covers androgen supplementation in cisgender women, including medical contexts. Its findings cannot turn a particular nonmedical drug, route or dose into a risk-free choice.
In the nine-patient voice clinic series, five returned after treatment and described some subjective benefit. The study began with people who already had complaints, and improvement was not the same as a documented return to their original voice.
Most were receiving hormones for reasons other than muscle gain. This is important clinical evidence about a possible adverse effect, not a representative survey of female bodybuilders.
The twenty-year case is also more complicated than a voice that simply stayed unchanged: a procedure initially improved function, and new weakness with vocal-fold atrophy appeared years later. The authors discussed possible explanations rather than proving one cause for the late changes.
Persistence therefore does not mean that help is pointless, and treatment-related improvement does not guarantee restoration. New or persistent hoarseness, instability or loss of range deserves medical assessment, which may include a specialist voice team.
Periods, fertility and pregnancy are different outcomes
A review of sport, doping and female fertility describes how AAS can disrupt reproductive hormone signaling, periods and ovulation. Low energy availability and other medical conditions can also affect cycles, so an absent period needs assessment rather than an assumption about its cause.
Bleeding, ovulation, conception and a healthy pregnancy are distinct outcomes. Evidence that periods can return does not provide a personal fertility forecast or prove that every other effect has resolved.
The US methyltestosterone label contraindicates use in women who are or may become pregnant and warns of fetal genital virilization. Pregnancy or possible pregnancy requires prompt contact with a medical professional for advice about current exposure.
The extensive 2024 review of female AAS effects also discusses offspring research in animals and associations involving prenatal hormones in humans. Those findings should not be presented as a proven list of future conditions in a child after a particular maternal exposure.
Skin, hair and genital changes need separate expectations
Acne, unwanted hair growth and scalp hair loss can affect comfort, confidence and daily life. Improvement in acne is not equivalent to reversal of scarring, and scalp hair may not return despite treatment.
Clitoral enlargement may also persist after exposure ends. The methyltestosterone label specifically warns about irreversible virilization, but a drug label is not a recovery study of every illicit compound or combination.
Discussing these effects should be respectful and factual. A person’s appearance cannot establish what they used, their symptoms or how they feel about a change.
Claims that AAS routinely and permanently remodel adult female facial bones go beyond the evidence established here. Changes in facial appearance alone cannot demonstrate a change in bone structure.
Heart and liver risks may be less visible
Looking strong does not reveal blood pressure, cholesterol, liver function or heart structure. Shared AAS risks include adverse lipids, cardiovascular problems and liver injury, particularly with certain orally active compounds.
Female-specific evidence is uneven: the 2024 review draws on male studies, animal experiments and clinical reports as well as research in women. It explicitly notes gaps in comparable female cardiovascular data.
That limits personal risk estimates and recovery forecasts. It does not make a normal-looking physique or one reassuring laboratory result a comprehensive health assessment.
Chest pain, severe breathlessness or fainting needs urgent medical attention. Yellowing of the skin or eyes, dark urine or significant abdominal pain also warrants prompt medical advice.
Mood and withdrawal deserve care
Mood swings, anxiety, depression and dependence can occur with nonmedical AAS use. Withdrawal may include fatigue, sleep problems and low mood, as described by the NHS and the methyltestosterone label.
These symptoms are a reason to involve a qualified clinician in stopping and follow-up care. This article cannot determine whether a particular person needs a medication change, taper or other treatment.
Seek urgent help if you feel at immediate risk of harming yourself or develop severe mental health symptoms. Pregnancy concerns and other urgent symptoms also need prompt attention rather than waiting for a routine recovery timetable.
The NHS states that cycling, stacking and pyramiding have not been shown to reduce AAS harms. Adding another hormone or a product marketed for post-cycle recovery is not a substitute for medical assessment.
How to read a claim that an effect is reversible
Look for the people studied, the actual outcome and what happened after exposure ended. A claim can sound reassuring while skipping one of those steps.
| Claim you might encounter | Question worth asking | More accurate interpretation |
|---|---|---|
| My period returned, so everything recovered. | Were ovulation, fertility and other organs assessed? | One reported change cannot establish every health outcome. |
| Five patients improved, so treatment usually reverses it. | Who entered the study, who returned and what counted as improvement? | The voice series had nine selected clinic patients and five follow-ups; subjective benefit was not full restoration. |
| The study found no reported voice problem. | Did it also measure pitch, and did that result agree? | The randomized analysis separated acoustic changes from perceived voice impact. |
These are examples of reading evidence, not a home screening or clearance tool. Neither a symptom checklist nor an online discussion can predict an individual’s response.
What to bring to an appointment
Bring product names or label photographs, the amounts you believe you took, dates, routes and other medicines or supplements. Include menstrual history, contraception, pregnancy possibility and any physical or mood changes.
Write down when each change began and whether it continued after exposure ended. Separate what improved on its own from what changed after medical treatment.
Ask which symptoms need specialist assessment and which examinations or tests are appropriate for your history. Be clear about missing information, including uncertainty about what a nonmedical product actually contained.
The aim is confidential, accurate care without shame. Persistent effects are possible, and the available human evidence does not support a guaranteed reset after a cycle.
Sources and reading scope
- Huang and colleagues, 2015: randomized testosterone voice analysis, including its available-data denominators and exploratory limitations; full primary report reviewed.
- Bensoussan and Anderson, 2019: twenty-year voice case with procedures and later changes; full primary report reviewed.
- Chadwick and colleagues, published 2021: nine-patient voice clinic series; PubMed abstract reviewed.
- Havnes and colleagues, published 2021: interviews with 16 current or former AAS users; PubMed abstract reviewed.
- Majeethia and colleagues, 2025: 14-study voice scoping review; PubMed abstract reviewed.
- La Vignera and colleagues, 2018, and Santos and colleagues, 2024: reviews of reproductive and wider female AAS evidence; human findings distinguished from animal and mechanistic work.
- NHS, Mayo Clinic and the US methyltestosterone label: clinical risk and care information, not individualized recovery predictions.
These sources cover different populations and exposures. Their findings are not interchangeable with a particular nonmedical bodybuilding regimen.
Get the next evidence check.
Five practical fitness stories worth your time, every Friday.
One email a week. No product pitches. Unsubscribe in one click.
Medical disclaimer: This article provides general health information, not a diagnosis or individualized medical advice. Consult a qualified medical professional about hormone exposure, symptoms, pregnancy concerns or changes to medication.
